Hims & Hers added eight new partners, expanding its Benefits program across fitness, nutrition, glucose monitoring, women's health and sleep. ・The company recently launched generic Semaglutide in ...

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the expansion of Hims & Hers ...

HIMS expands its integrated telehealth ecosystem with a new weight-loss membership and a planned Eucalyptus acquisition to broaden virtual care.

Hims & Hers Health (HIMS) stock is in the spotlight as four-star-rated analyst Allen Lutz from Bank of America Securities reiterated his Sell rating, despite the company’s recent rollout of new ...

We recently published 10 Stocks Stealing Today’s Spotlight; 5 on All-Time Highs. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the best performers on Wednesday. Hims & Hers soared by 16.18 percent on ...

Andrew Dudum is a disrupter. In 2017 he founded Hims & Hers (NYSE: HIMS), a digital health startup with the goal of upending the traditional healthcare market. Today, Hims & Hers includes women’s ...

Much of the excitement over Hims & Hers has been connected to the company's sales of compounded versions of GLP-1 inhibitor semaglutide. Novo Nordisk markets semaglutide as a treatment for type 2 ...

Hims & Hers' model is simple. It has two separate web platforms -- Hims for men and Hers for women -- that sell medications and deliver to customers' front doors. It began with sexual health, but has ...

Yahoo Finance Senior Reporter Brooke DiPalma and Market Domination host Josh Lipton discuss some of Monday's top trending stories. Ticketmaster parent company Live Nation (LYV) reached a settlement in ...

Shares of Hims & Hers Health (NYSE:HIMS) are under pressure after JPMorgan trimmed its price target on the consumer telehealth name following a messy first quarter. The firm lowered its price target ...